Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Ardent Health Partners, Inc. (ARDT) and Caribou Biosciences (CRBU)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY – Research Report), Ardent Health Partners, Inc. (ARDT – Research Report) and Caribou Biosciences (CRBU – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Eli Lilly & Co (LLY)
Barclays analyst Emily Field maintained a Buy rating on Eli Lilly & Co today and set a price target of $1350.00. The company’s shares closed last Friday at $990.33.
According to TipRanks.com, Field is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1261.00 average price target, which is a 29.3% upside from current levels. In a report issued on February 24, RBC Capital also initiated coverage with a Buy rating on the stock with a $1250.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Ardent Health Partners, Inc. (ARDT)
In a report released today, Matthew Gillmor CFA from KeyBanc maintained a Hold rating on Ardent Health Partners, Inc.. The company’s shares closed last Friday at $8.90.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
Ardent Health Partners, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $12.69, which is a 37.2% upside from current levels. In a report issued on March 5, TipRanks – xAI also reiterated a Hold rating on the stock with a $10.50 price target.
Caribou Biosciences (CRBU)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Caribou Biosciences on March 6 and set a price target of $9.00. The company’s shares closed last Friday at $1.82.
According to TipRanks.com, Burns is a 5-star analyst with an average return of
Caribou Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $8.33, which is a 401.8% upside from current levels. In a report issued on February 20, Citi also maintained a Buy rating on the stock with a $8.00 price target.
